These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time. Carducci MA Urology; 2000 Feb; 55(2):157-60. PubMed ID: 10688070 [No Abstract] [Full Text] [Related]
5. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! Collette L; Buyse M; Burzykowski T J Clin Oncol; 2007 Dec; 25(35):5673-4; author reply 5674. PubMed ID: 18065747 [No Abstract] [Full Text] [Related]
6. [Treatment of prostate cancer]. Imre R Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544 [No Abstract] [Full Text] [Related]
7. Serial monitoring of patients with prostate cancer treated with anti-androgen therapy. Stamey TA Cancer; 1992 Nov; 70(9):2378. PubMed ID: 1382833 [No Abstract] [Full Text] [Related]
9. Do we really need new trials on fulvestrant in prostate cancer? Féchon A; Droz JP Onkologie; 2010; 33(1-2):12-3. PubMed ID: 20164656 [No Abstract] [Full Text] [Related]
10. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]. Akimoto S; Masai M; Kitagawa N; Nakamura T; Shimazaki J Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):450-6. PubMed ID: 7685840 [TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of early prostate cancer]. Kaprin AD; Khalil Farzat M; Gafanov RA; Kostin AA Vopr Onkol; 2009; 55(3):382-5. PubMed ID: 19670743 [No Abstract] [Full Text] [Related]
12. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program]. Mansueto G; Longo F Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169 [No Abstract] [Full Text] [Related]
13. Systemic treatment and new developments in advanced prostate cancer. Sternberg CN Eur J Cancer; 2001 Oct; 37 Suppl 7():S147-57. PubMed ID: 11887986 [No Abstract] [Full Text] [Related]
14. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Ruckle HC; Klee GG; Oesterling JE Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870 [TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472 [TBL] [Abstract][Full Text] [Related]
16. Introduction by the Guest Editor: The Rapidly Evolving Treatment Landscape of Prostate Cancer-The Convergence of Treatment Paradigms of Localized and Metastatic Diseases. Spratt DE Cancer J; 2020; 26(1):1. PubMed ID: 31977378 [No Abstract] [Full Text] [Related]
17. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515 [TBL] [Abstract][Full Text] [Related]